Background: MLLT2 is involved in acute leukemias through a chromosomal translocation t(4;11)(q21;q23) that involves mllt2 and mll/hrx. AF-4 (MLLT2), AF-9, and ENL proteins contain nuclear targeting sequences as well as serine-rich and proline-rich regions. Stretches abundant in basic amino acids are also present in the three proteins. These results suggest that the different proteins fused to ALL-1 polypeptide(s) provide similar functional domains. AF4 is a serine- and proline-rich putative transcription factor with a glutamine-rich carboxyl terminus. The composition of the complete MLL-AF4 fusion product argues that it may act through either a gain-of-function or a dominant negative mechanism in leukemogenesis.
Other Names: AF4/FMR2 family member 1, ALL1-fused gene from chromosome 4 protein, Protein AF-4, Protein FEL, Proto-oncogene AF4, AFF1, AF4, FEL, MLLT2, PBM1
Target/Specificity: The synthetic peptide sequence used to generate the antibody AP6189a was selected from the C-term region of human MLLT2 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: AFF1
Gene ID: 4299 Primary Accession: P51825 Other Accession: NP_005926 Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
